

References

S-213

1. Bakhuraysah M, Siatskas C, Petratos S. Hematopoietic stem cell transplantation for multiple sclerosis: Is it a clinical reality? *Stem Cell Res Ther.* 2016;7:12
2. Malmegrim K, Azevedo J, Amuda L, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes. *Front Immunol.* 2017;8:167.
3. Farge D, Arruda L, Brigant F, et al. Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. *J Hematol Oncol.* 2017;10:21.
4. Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. *JAMA Neurol.* 2017;74(4):459-469.
5. Atkins HL, Bowman M, Allan D., et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial. 2016;576-585.
6. Snowden JA, Sharrack B, Akil M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - A guide for the generalist. *Clinical Medicine (London, England).* 2018;18(4):329-334.
7. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. 2016;87(4):419-425.
8. Sullivan K, Goldmuntz E, Keyes-Elstein L, et al. Myeloblastic autologous stem-cell for severe scleroderma. *Engl J Med.* 2018;378(1):35-47.
9. Host L, Nikpour M, Calderone A, Cannell P, Roddy J. Autologous stem cell transplantation in systemic sclerosis: A systematic review. *Clin Exp Rheumatol.* 2017;35 Suppl 106(4):198-207.
10. Patel L, Lim YJ, Randomized trials of autologous hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: Systematic review and meta-analysis with trial sequential analysis of overall mortality. 2018;132:612.
11. Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. *JAMA Neurol.* 2017;74(4):459-469.
12. Hayes, Inc. Hayes Health Technology Assessment. *Autologous hematopoietic stem cell transplantation for the treatment of systemic sclerosis.* Lansdale, PA: Hayes, Inc.; 7/19/2019.
13. Sullivan KM, Majhail NS, Bredeson C, et al. Systemic sclerosis as an indication for autologous hematopoietic cell transplantation” position statement

- from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2018;24:1961-1964.
14. Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A. Autologous hematopoietic stem cell transplantation for systemic sclerosis: A systematic review and meta-analysis. *Biol Blood Marrow Transplant*. 2018;24(5):937-944.
 15. Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. *JAMA*. 2019;321(2):165-174.
 16. Sormani MP, Muraro PA, Schiavetti I, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. *Neurol*. 2017;88(22):2115-2122.
 17. Ge F, Lin H, Li A, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis. *Neurol Sci*, 2019;40(3):479-487.
 18. Snarski E, Milczarczyk A, Halaburda K, et al. Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: Long-term observations. *Bone Marrow Transplant*. 2016;51(3):398-402.
 19. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. *Neurol*. 2017;88(9):842–852.
 20. Leone A, Radin M, Almarzooqi AM, et al. Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. *Autoimmun Rev*. 2017;16(5):469-477.
 21. Leng XM, Jiang Y, Zhou DB, et al. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: A 10-year follow-up study. *Clin Exp Rheumatol*. 2017;35(3):494-499.
 22. Cao C, Wang M, Sun J, et al. Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: The observation of long-term outcomes in a Chinese centre. *Clin Exp Rheumatol*. 2017;35(3):500-507.
 23. Burt RK, Han X, Gozdziaik P, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: Effect of conditioning regimen on outcome. *Bone Marrow Transplant*. 2018;53(6):692-700.
 24. M F Silva J, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. *Blood Adv*. 2018;2(7):777–786.
 25. El-Badawy A, El-Badri N. Clinical efficacy of stem cell therapy for diabetes mellitus: A meta-analysis. *PLoS One*. 2016;11(4):e0151938.

26. Cantu-Rodriguez OG, Lavalle-Gonzalez F, Herrera-Rojas MA, et al. Long-term insulin independence in type 1 diabetes mellitus using a simplified autologous stem cell transplant. *J Clin Endocrinol Metab.* 2016;101(5):2141-2148.
27. Walicka M, Milczarczyk A, Snarski E, et al. Lack of persistent remission following initial recovery in patients with type 1 diabetes treated with autologous peripheral blood stem cell transplantation. *Diabetes Res Clin Pract.* 2018;143:357-363.
28. Lindsay JO, Allez M, Clark M, et al. Autologous stem-cell transplantation in treatment-refractory Crohn's disease: An analysis of pooled data from the ASTIC trial. *Lancet Gastroenterol Hepatol.* 2017;2(6):399-406.
29. Brierley CK, Castilla-Llorente C, Labopin M, et al. Autologous haematopoietic stem cell transplantation for Crohn's disease: A retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. *J Crohns Colitis.* 2018;29;12(9):1097-1103.
30. Bryant A, Atkins H, Pringle CE, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. *JAMA Neurol.* 2016;73(6):652-658.
31. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurol.* 2016;87(4):419-425.
32. Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurol.* 2018;90(17):789-800.
33. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurol.* 2018;90(17):777-788.
34. Cohen JA, Baldassari LE, Atkins HL et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation. *Biol. Blood Marrow Transplant.* 2019;25(5).
35. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis.* 2017;76(8):1327-1339.
36. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2018;113(4):481-517.

37. Kvistad SAS, Lehmann AK, Trovik LH, et al. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. *Mult Scler.* 2020;26(14):1889-1897.
38. Henes J, Oliveira MC, Labopin M, et al. Autologous stem cell transplantation for progressive systemic sclerosis: A prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. *Haematol.* 2020.
39. van Bijnen S, de Vries-Bouwstra J, van den Ende CH, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: Results of a long-term follow-up multicentre study. *Ann Rheum Dis.* 2020;79(8):1084-1089.
40. Burt RK, Balabanov R, Tavee J, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. *J Neurol.* 2020;267(11):3378-3391.
41. Sun SY, Gao Y, Liu GJ, et al. Efficacy and safety of stem cell therapy for T1DM: An updated systematic review and meta-analysis. *J Diabetes Res.* 2020;5740923.
42. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. *Neurol.* 2020;96(3):114-122.